Dr Reddy’s Laboratories launched its injectable semaglutide under the brand name Obeda for the management of type 2 diabetes in the Indian market. Dr Reddy’s is the first Indian company to receive ...

Highlighting property taxes and household expenses, radio host Chris Reddy has launched a 2026 campaign for Connecticut’s 29th State Senatorial District. Reddy, a Republican who lost a close race for ...

JAGTIAL / HYDERABAD: Former minister and senior leader T Jeevan Reddy on Wednesday ended his four-decade association with the Congress, announcing his resignation in Jagtial in the presence of ...

WASHINGTON, DC – The Center for Strategic and International Studies (CSIS), a bipartisan, nonprofit policy research organization dedicated to advancing practical ideas to address the world’s greatest ...

Republican candidate Rom Reddy held a campaign event in Greenville for his gubernatorial run. Reddy is running on a platform of shrinking government, cutting taxes, and reforming education. Some ...

MOUNT PLEASANT, S.C. (WCBD) – Businessman Rom Reddy, who recently announced his plan to seek the Republican nomination for South Carolina governor, discussed his campaign, views on state government, ...

Emotions ran high when senior Congress leader and former Minister T. Jeevan Reddy resigned from the Congress expressing his anguish over the ‘insults and humiliation’ meted out to him and the loyal ...

HE WILL BE IN ATTENDANCE IN HOPES TO UNDERSTAND MORE THEN. TURNING TO COMMITMENT. 2026 REPUBLIC REPUBLICAN GUBERNATORIAL CANDIDATE RON MORETTI WAS IN THE UPSTATE TODAY. THE BUSINESSMAN AND ...

Hyderabad: NATHEALTH, an apex body representing the Indian healthcare industry, has announced Dr. Sangita Reddy, Joint Managing Director, Apollo Hospitals Group as its new President for FY 2026-2027.

Sun Pharmaceutical, Dr. Reddy’s Laboratories, Zydus Life Sciences, and Glenmark Pharmaceuticals rolled out generic versions of Semaglutide on March 21, following the expiration of the patent on the ...

India’s weight-loss drug market is on the verge of a price shake-up. In days, domestic drugmakers are set to launch cheaper versions of semaglutide, the GLP-1 (glucagon-like peptide-1) therapy popular ...